MultiTEP platform–based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency

We have previously demonstrated that anti-beta amyloid DNA vaccine (AV-1959D) based on our proprietary MultiTEP platform technology is extremely immunogenic in mice, rabbits, and monkeys. Importantly, MultiTEP platform enables development of vaccines targeting pathological molecules involved in vari...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of aging 2017-11, Vol.59, p.156-170
Main Authors: Davtyan, Hayk, Zagorski, Karen, Petrushina, Irina, Kazarian, Konstantin, Goldberg, Natalie R.S., Petrosyan, Janet, Blurton-Jones, Mathew, Masliah, Eliezer, Cribbs, David H., Agadjanyan, Michael G., Ghochikyan, Anahit
Format: Article
Language:English
Subjects:
alpha-Synuclein - immunology
Animals
Anti-α-synuclein antibodies
Antibodies
B-cell mapping
DNA vaccines
Epitopes, B-Lymphocyte - immunology
Female
Humans
Immunogenicity
Mice, Inbred C57BL
Mice, Transgenic
MultiTEP platform
Neurodegenerative Diseases - genetics
Neurodegenerative Diseases - immunology
Neurodegenerative Diseases - therapy
T-cell mapping
T-Lymphocytes, Helper-Inducer - immunology
Therapeutic potency
Vaccines, DNA - immunology
Vaccines, DNA - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have previously demonstrated that anti-beta amyloid DNA vaccine (AV-1959D) based on our proprietary MultiTEP platform technology is extremely immunogenic in mice, rabbits, and monkeys. Importantly, MultiTEP platform enables development of vaccines targeting pathological molecules involved in various neurodegenerative disorders. Taking advantage of the universality of MultiTEP platform, we developed DNA vaccines targeting 3 B-cell epitopes (amino acids [aa]85-99, aa109-126, and aa126-140) of human alpha-synuclein (hα-Syn) separately or all 3 epitopes simultaneously. All 4 DNA vaccines (1) generate high titers of anti-hα-Syn antibodies and (2) induce robust MultiTEP-specific T-helper cell responses without activation of potentially detrimental autoreactive anti-hα-Syn T-helper cells. Generated antibodies recognize misfolded hα-Syn produced by neuroblastoma cells, hα-Syn in the brain tissues of transgenic mouse strains and in the brain tissues of dementia with Lewy body cases. Based on these results, the most promising vaccine targeting 3 B-cell epitopes of hα-Syn simultaneously (PV-1950D) has been chosen for ongoing preclinical assessment in mouse models of hα-Syn with the aim to translate it to the human clinical trials.
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2017.08.006